SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp XCN price spike, with traders citing a large candle and a sizable short-term gain but no clear news catalyst, is driving attention. The community is split between buying the dip and expecting a rebound, and warning that the recurring pumps quickly fade into sell-offs.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Reports that Papa Johns largest U.S. franchisee has joined Irth Capitals take-private effort are driving buyout speculation. Traders see the franchisees involvement as strengthening the bid, while others remain skeptical the board will accept a deal given its past decisions and the companys weak operating performance.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is rallying with cybersecurity peers as AI-related security concerns and newly publicized vulnerabilities reinforce expectations for stronger enterprise security spending; traders also point to a bullish channel-partner survey suggesting budgets are firming. The move has drawn bullish momentum trading, while some investors question whether elevated valuations already reflect that demand.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is drawing attention after a rally tied to the PHP2Shell web-server vulnerabilities, which prompted concern about widespread attacks and potential demand for Cloudflares WAF and traffic-protection services. Traders are framing the security scare as a possible business tailwind, while some focus on the sharp move and question whether it can continue.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 DeLLphi-305 results for IMDELLTRA plus AstraZenecas IMFINZI in first-line small-cell lung cancer are driving attention, with traders highlighting the reported survival benefit and potential to expand IMDELLTRAs role. The community is weighing that pipeline opportunity against Repathas established sales growth as a key near-term business driver.

TOSHI

TOSHI is drawing attention amid a tentative rebound and rising-volume chatter, with traders watching whether it can break through repeated technical resistance and trigger a short squeeze. Bulls are accumulating and anticipating a breakout, while skeptics point to the tokens prolonged weakness and risk of further lows; no specific catalyst is confirmed.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEOs sale of its Adelanto ICE facilities to DHS, followed by debt repayment and greater flexibility for share buybacks, dominates the discussion. Bulls see the transaction as strengthening the balance sheet and supporting shareholder returns, while others question why the stock weakened and worry about the implications of selling facilities for future operations.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

IBB is drawing attention for a modest decline while testing its 50-day moving average. Traders largely describe the pullback as a pause rather than a clear trend reversal, noting that large-cap biotech is holding up better than smaller biotech stocks, though broader sector weakness and rate concerns remain in the discussion.

Wormhole is a cross-chain messaging protocol that enables secure transfers of data or tokens across different blockchain networks. It supports a variety of applications, including DeFi, NFTs, and governance, by allowing data to be moved between blockchains efficiently and securely. Wormhole employs multiple verification methods to ensure the integrity and validity of the data transmitted through its network.

Wormhole

Traders are highlighting Wormholes integration with Ripple and the XRP Ledger, viewing expanded cross-chain interoperability as a potential adoption catalyst. Bullish calls for a breakout contrast with frustration over weak price action and concerns about token unlocks and selling pressure.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

ESMO subgroup analyses from Celcuitys Phase 3 VIKTORIA-1 study are driving discussion, with traders highlighting favorable results for the gedatolisib triplet in PIK3CA-mutant breast cancer; the topline findings had been reported previously. Reactions are largely encouraged by the data, while some traders argue the stock still needs proof of commercial sales and execution, and the timing of an FDA label-expansion decision remains uncertain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.

Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine

Human clinical development is putting one of aging biology’s most closely watched proteins on the biotechnology radar   New York, NY – September 30, 2026 – Klotho is quickly becoming one of the more interesting names in longevity research. What started largely as a research question around aging and biological decline is now moving closer […]
The post Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine appeared first on Financial News Media.

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.

Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?

BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +5.56% and +143.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Will Recent Setbacks Impact Growth Prospects of DNLI Stock?

Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.

DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?

Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.

Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II

RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Denali Therapeutics Inc

BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Despite the miss, the companies said the medicine was generally well tolerated with an acceptable safety profile and demonstrated strong target engagement in the body.</li><li>Biogen and Denali will stop further development of BIIB122 for the broader idiopathic form of Parkinson’s.&nbsp;</li><li>Denali will continue its separate early-to-middle BEACON study of the same drug, but only in the smaller group of patients who carry a specific genetic mutation.</li></ul>Shares of Biogen Inc. (BIIB) slipped about 1% in after-hours trading on Thursday after the company and partner Denali Therapeutics (DNLI) announced that their mid-stage LUMA study of an experimental Parkinson’s disease drug failed to meet its primary and secondary goals.&nbsp;DNLI stock, meanwhile, fell 7% after hours.&nbsp;The late-stage trial tested BIIB122, also known as DNL151, a small-molecule pill designed to block overactive LRRK2 — a protein linked to Parkinson’s — in hopes of slowing disease progression in people with early-stage idiopathic Parkinson’s. The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, as measured by a standard Parkinson’s rating scale.Parkinson's Disease is a progressive neurological disorder caused by the loss of dopamine-producing neurons in the brain. It leads to unintended movement issues, as well as non-motor symptoms like cognitive impairment, depression, and sleep problems.<h2 class="st-heading-2">What Next For The Experimental Therapy?</h2>Despite the miss, the companies said the medicine was generally well tolerated with an acceptable safety profile and demonstrated strong target engagement in the body. As a result, Biogen and Denali will stop further development of BIIB122 for the broader idiopathic form of Parkinson’s.Denali will continue its separate early-to-middle BEACON study of the same drug, but only in the smaller group of patients who carry a specific genetic mutation that over-activates LRRK2. Results from that trial are expected in the first half of 2027.“While these are not the results we hoped for, these data provide important information to the Parkinson’s community and will be presented at an upcoming scientific conference,” said Diana Gallagher, Senior Vice President and Head of Neurodegeneration Clinical Development at Biogen.Peter Chin, Chief Medical Officer at Denali Therapeutics, added that the companies will analyze the full data set alongside upcoming BEACON results to decide next steps.<h2 class="st-heading-2">How Did DNLI, BIIB Retail Traders React?</h2>On Stocktwits, retail sentiment around BIIB and DNLI stocks were ‘bearish’ at the time of writing, coupled with ‘high’ message volume.While <a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> has gained 49% over the past 12 months, <a href="https://stocktwits.com/symbol/DNLI">DNLI</a> added 41%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/imax-stock-soars-after-hours-following-news-of-early-stage-sale-process/cZXCS88Re8Z">IMAX Stock Soars After Hours Following News Of Early-Stage Sale Process</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, the company said. 

Biogen Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

DNLI Denali Therapeutics Inc

Fundamentals

Latest DNLI News